---
title: "T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251401534.md"
description: "T&K Holdings' subsidiary Bochuangyuan's CKBA ointment has achieved preliminary results in Phase II clinical trials for vitiligo, showing good efficacy and safety, meeting the expected goals. These results support the continuation of Phase III clinical trials and will be submitted to the CDE for breakthrough therapy application. As the first innovative drug targeting the T cell fatty acid metabolism pathway, CKBA demonstrates development potential in the field of autoimmune diseases. The company will accelerate the advancement of related clinical trials and basic research"
datetime: "2025-08-04T07:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251401534.md)
  - [en](https://longbridge.com/en/news/251401534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251401534.md)
---

# T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals

According to the Zhitong Finance APP, T&K (301263.SZ) announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has recently completed data organization and unblinding for the Phase II clinical trial of its independently developed Class I innovative drug CKBA ointment for the treatment of vitiligo. Preliminary results indicate that CKBA ointment shows positive efficacy and good safety in patients with non-segmental vitiligo. The trial results are ideal and meet the expected goals, supporting the continuation of Phase III confirmatory clinical trials. Relevant research data will also be submitted to the CDE for breakthrough therapy application and communication regarding clinical registration in the near future.

The preliminary results of the Phase II clinical trial for CKBA ointment in the treatment of vitiligo have met the expected goals, further validating CKBA as the first-in-class (FIC) innovative small molecule drug targeting T cell fatty acid metabolism pathways, demonstrating significant development potential in the field of autoimmune diseases. The company will accelerate the advancement of Phase III clinical trials for vitiligo and Phase II/III clinical trials for rosacea, while continuing to conduct in-depth basic research on CKBA's targets and mechanisms of action, further expanding its related indications in the field of autoimmune diseases

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [14:56 ETInvestment Watches Ranks No. 9 on 2026 Inc. 5000, Named Austin's Fastest-Growing Private Company](https://longbridge.com/en/news/295569295.md)
- [Contour Asset Management discloses net short position in Publicis Groupe](https://longbridge.com/en/news/295415649.md)
- [Volare launches share issue as Pori commercial-scale plant comes online](https://longbridge.com/en/news/295769322.md)
- [North Korean hackers turn to AI as DPRK drives 66% of crypto hack losses](https://longbridge.com/en/news/295368534.md)
- [Herb Dock Launches Eye Scan Platform for Personalized Wellness](https://longbridge.com/en/news/295456534.md)